Funding to expand Opentrons life sciences and healthcare automated laboratory platform

September 23, 2021 08:00 EDT

NEW YORK--(BUSINESS WIRE)--Today, Opentrons Labworks Inc. announced that SoftBank Vision Fund 2* has led a $200 million Series C investment in the company, with participation from Khosla Ventures. Opentrons will use the funding to further invest in its global automated laboratory platform.

"Biology opens the door to solving many of humanity's grand challenges. For too long, scientists and clinicians have been shackled by the slow, expensive, and overly complex laboratory solutions that underpinned their work"

"Biology opens the door to solving many of humanity's grand challenges. For too long, scientists and clinicians have been hamstrung by the slow, expensive, and overly complex laboratory solutions that underpinned their work." Opentrons CEO Jon Brennan-Badal said. "Opentrons' platform provides the key to unlocking its potential. We are driving more R&D, more testing, more biology to unlock innovation in life sciences and healthcare."

This laboratory platform uniquely integrates the development of laboratory robotics, analysis and operations to create high-quality and cost-effective end solutions. Opentrons uses the platform to provide the following industry-specific laboratory solutions:

• Health System Diagnostic Laboratory Services：通過子公司流行病應對實驗室發展空間，該公司將該平臺用于自己的子公司實驗室解決問題，提供價格低廉、高通量的分子診斷測試效率。 去年，美國各地的醫(yī)院和衛(wèi)生系統(tǒng)已使用這些檢測實驗室服務對超過 450 萬名患者進行了檢測發揮效力。
• Laboratory automation robots for life science R&D：通過 Opentrons Robotics 業(yè)務部門更適合，該公司銷售價格實惠的實驗室機器人不斷發展，以幫助生命科學研發(fā)實驗室實現(xiàn)操作自動化。 Opentrons 的旗艦產(chǎn)品 OT-2 機器人被 40 多個國家的數(shù)千個研究組織使用合規意識。 在整個 COVID-19 大流行期間密度增加，OT-2 機器人被部署到世界各地的醫(yī)院實驗室來測試數(shù)百萬患者樣本。
• Genome-scale cell engineering for biopharmaceuticals：通過 Neochromosome 子公司現場，該公司開發(fā)并部署了其生物鑄造廠高端化，該工廠具有獨特的能力，能夠以前所未有的通量合成基因組規(guī)模的 DNA 構(gòu)建體我有所應。 利用最近收購的 Zenith AI 的合作提單產，該公司正在為治療藥物的發(fā)現(xiàn)、開發(fā)和生物制造創(chuàng)造變革性解決方案至關重要。

"Opentrons is building a disruptive automated laboratory platform designed to transform healthcare and life sciences with vertically integrated, low-cost solutions," said Angela Du, investment director at SoftBank Investment Advisors. “The company has an extremely high value proposition in the laboratory diagnostics and synthetic genomics markets, where its robots and consumables are now fundamental components. We look forward to working with CEO Jonathan Brennan-Badal to help the company accelerate growth and bring new Product commercialization.”

The Series C round will bring significant investment into the Opentrons platform. In particular, the investment will support the development of new robotic tools, an expanded biofoundry, new diagnostic tests and additional diagnostic laboratories. All of these initiatives will lead to better, more affordable solutions for our life sciences and healthcare customers.

OPENTRONS Announces Key New Team Additions to Scale Platform:

• Myrtle Potter發展空間，Opentrons Labworks, Inc. 董事會主席。Myrtle 現(xiàn)任 Sumitovant 首席執(zhí)行官有所應。 前身為 Roivant Sciences足了準備、Genentech、BMS著力提升、Merck幅度。
• Greg Greeley,Opentrons Labworks, Inc. 總裁兼首席運營官。Greg 曾任 Airbnb 總裁重要的作用、亞馬遜歐洲業(yè)務副總裁貢獻，并領導亞馬遜全球 Prime 計劃。 Greg 將加入 Opentrons 董事會穩中求進。
• Roberts. Langer, Neochromosome, Inc. 科學顧問委員會主席統籌。麻省理工學院研究所教授。 Moderna 聯(lián)合創(chuàng)始人協同控製。
• JE FBO EKe, PRL 科學顧問委員會主席振奮起來、Sol 和 Judith Bergstein 系統(tǒng)遺傳學研究所所長、紐約大學朗格尼分校生物化學和分子藥理學系教授利用好。 PRL 和 Neochromosome 的聯(lián)合創(chuàng)始人深入各系統。

About OPENTRONS LABWORKS INC., SUBSIDIARIES AND INVESTORS

• openSame as Ron slab works Inc. Opentrons 開發(fā)綜合實驗室平臺，通過 Opentrons Robotics尤為突出、Pandemic Response Lab 和 Neochromosome 子公司為生命科學和醫(yī)療保健客戶提供服務規定。
• open TR ONS robotics 是 Opentrons Labworks Inc 的一個業(yè)務部門環境，是靈活空間載體、用戶友好的實驗室自動化領域的行業(yè)領導者高質量。 Opentrons Robotics 的旗艦產(chǎn)品 OT-2 遍布 40 多個國家的數(shù)千個實驗室。 這些機器人可以在 https://opentrons.com/ 購買
• pandemic response lab (PRL) 是 Opentrons Labworks Inc. 的全資子公司重要組成部分，該公司利用該平臺為美國各地的衛(wèi)生系統(tǒng)提供診斷實驗室服務流程。 您可以訪問 https://pandemicresponselab.com/ 了解有關(guān) PRL 診斷實驗室服務產(chǎn)品的更多信息
• neochromosome (neo) 是 Opentrons 于 2021 年 3 月收購的全資子公司。Neo 利用 Opentrons 平臺創(chuàng)建用于治療的基因組規(guī)模細胞工程解決方案勃勃生機。 您可以訪問 https://neochromosome.com/ 了解有關(guān) Neo 基因組規(guī)模細胞工程解決方案的更多信息
• zenith AI是 Opentrons 于 2021 年 6 月收購的全資子公司助力各業。Zenith AI 為 Opentrons 平臺帶來了專有的無代碼人工智能和現(xiàn)代機器學習。 您可以在 https://www.zenify.ai/ 了解有關(guān) Zenith AI 的更多信息
• soft bank group corp. 是一家日本跨國集團控股公司提供有力支撐，總部位于東京港區(qū)應用。 該集團主要投資于技術(shù)、能源和金融領域的公司品率。
• Other investors in Opentrons包括 Sands Capital相貫通、Lerer Hippeau Ventures、SOSV 和 Y Combinator積極影響。

*As of the date of this press release, SoftBank Group Corporation has made investments that allow the SoftBank Vision Fund 2 ("SVF 2") to invest in certain portfolio companies. The information contained herein is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy limited partnership interests in any fund, including SVF 2. There has been no external closing of SVF 2, and any potential third-party investors should receive further information related to any SVF 2 investment prior to closing.